Product Description
We developed innovative, proprietary small molecules that target fat metabolism. This causes regression of MYC cancers in preclinical mouse and human studies and prolongs survival. Moreover, our novel metabolomic platform allows us to screen which cancers will respond to our treatment. We are able to monitor therapeutic response within a few days of treatment by measuring the actual biomarkers of our cancer therapy. This allows us to tell patients and doctors if our drug is working much faster than for standard cancer treatments. (Sourced from: https://www.linkedin.com/company/bacchus-therapeutics/)
Mechanisms of Action: Myc Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bacchus Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|